Galmed Pharmaceuticals Ltd. (GLMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GLMD Profit Margin, ROE & Profitability Analysis
GLMD vs Healthcare Sector: How Galmed Pharmaceuticals Ltd. Compares
How Galmed Pharmaceuticals Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Galmed Pharmaceuticals Ltd. Stock Overvalued? GLMD Valuation Analysis 2026
Based on fundamental analysis, Galmed Pharmaceuticals Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Galmed Pharmaceuticals Ltd. Balance Sheet: GLMD Debt, Cash & Liquidity
GLMD Revenue Growth, EPS Growth & YoY Performance
GLMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Galmed Pharmaceuticals Ltd. (CIK: 0001595353)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GLMD
What is the AI rating for GLMD?
Galmed Pharmaceuticals Ltd. (GLMD) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GLMD's key strengths?
Claude: Analysis in progress.
What are the risks of investing in GLMD?
Claude: Analysis in progress.
What is GLMD's revenue and growth?
Galmed Pharmaceuticals Ltd. reported revenue of N/A.
Does GLMD pay dividends?
Galmed Pharmaceuticals Ltd. does not currently pay dividends.
Where can I find GLMD SEC filings?
Official SEC filings for Galmed Pharmaceuticals Ltd. (CIK: 0001595353) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GLMD's EPS?
Galmed Pharmaceuticals Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GLMD's fundamental grade?
Based on our AI fundamental analysis in May 2026, Galmed Pharmaceuticals Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GLMD stock overvalued or undervalued?
Valuation metrics for GLMD: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GLMD's AI grade for 2026?
Our dual AI analysis gives Galmed Pharmaceuticals Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GLMD's free cash flow?
Galmed Pharmaceuticals Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does GLMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).